{"id":"W3204229826","doi":"10.1016/j.annonc.2021.08.1490","title":"1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Sirtex Medical; Servier; Astellas Pharma; Ipsen; BeiGene; Incyte; Taiho Pharmaceutical; Gilead Sciences; Merck KGaA; Daiichi Sankyo Europe; Halozyme; Sanofi; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Stryker; Amgen","keywords":"Medicine; Nivolumab; Internal medicine; Placebo; Adverse effect; Neoadjuvant therapy; Clinical endpoint; Gastroenterology; Esophageal cancer; Esophagectomy; Randomized controlled trial; Oncology; Surgery; Cancer; Pathology; Breast cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002101837,0.0002329392,0.0005913718,0.0002896843,0.0003052177,0.000480134,0.0002254604,0.0004026097,0.001084384],"category_scores_gemma":[0.0005930238,0.0001205164,0.0005469944,0.0003076278,0.000133945,0.0004406189,0.0002203854,0.0005754785,0.0003573975],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004005019,"about_ca_system_score_gemma":0.0002536318,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002886022,"about_ca_topic_score_gemma":0.004795938,"domain_scores_codex":[0.9998847,0.00001438894,0.00001204701,0.00002490647,0.00002228284,0.00004167034],"domain_scores_gemma":[0.9997246,0.00004081427,0.00006870788,0.0000222488,0.00004665802,0.00009684718],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.01221207,0.00106224,0.9088904,0.0001269728,0.0003992075,0.004057835,0.0001669449,0.0003671907,0.004541678,0.00003826813,0.001881596,0.06625567],"study_design_scores_gemma":[0.0001649134,0.00392345,0.9897726,0.00004079892,0.0004026617,0.001911007,0.000178977,0.0006498634,0.0009103887,0.00005519525,0.001973313,0.00001685807],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969278,0.001341408,0.00007255355,0.0001058636,0.00004331739,0.00002107944,0.0004225972,0.00001162282,0.001053919],"genre_scores_gemma":[0.9974471,0.0004189636,0.00005985535,0.0001057137,0.00003001243,0.00001143727,0.001076681,0.000002491586,0.0008477575],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002886022,"threshold_uncertainty_score":0.005738378,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07539090086295525,"score_gpt":0.4107412899619859,"score_spread":0.3353503890990307,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}